As of Dec 8, 2018 Zafgen Inc (NASDAQ:ZFGN) Shorts Declined By 20.49%

Zafgen, Inc. (NASDAQ:ZFGN) Corporate Logo

Zafgen Inc (NASDAQ:ZFGN) recorded a decrease of 20.49% in short interest. In December was announced ZFGN’s total 845,700 short interest by FINRA. That’s 20.49% down from 1.06M shares. Zafgen Inc (NASDAQ:ZFGN) has 222,900 shares average volume. It’ll cost 4 days for ZFGN to recover its previous position. 2.87% is Zafgen Inc float short.

The stock increased 0.79% or $0.04 during the last trading session, hitting $5.12.Zafgen, Inc. has volume of 163,960 shares. Since December 8, 2017 ZFGN has risen 207.35% and is uptrending. The stock outperformed the S&P500 by 191.73%.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity.The firm is worth $188.78 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases.Last it reported negative earnings.

Zafgen, Inc. (NASDAQ:ZFGN) Ratings Coverage

Total analysts of 2 have positions in Zafgen (NASDAQ:ZFGN) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since July 3, 2018 according to StockzIntelligence Inc Zafgen has 2 analyst reports.

For more Zafgen, Inc. (NASDAQ:ZFGN) news announced briefly go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Zafgen: Second-Generation MetAP2 Inhibitors Likely To Unlock Substantial Intermediate Value – Seeking Alpha” announced on June 15, 2018, “Zafgen: This Revaluation And Catalyst Story Is Still In Early Innings – Seeking Alpha” on August 17, 2018, “Company News For Nov 27, 2018 – Nasdaq” with a publish date: November 27, 2018, “Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study – GlobeNewswire” and the last “Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes – GlobeNewswire” with publication date: June 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.